MARKET

DNTH

DNTH

Dianthus Therapeutics Inc
NASDAQ
50.75
+4.17
+8.95%
After Hours: 50.75 0 0.00% 17:43 02/06 EST
OPEN
47.57
PREV CLOSE
46.58
HIGH
51.44
LOW
47.36
VOLUME
733.26K
TURNOVER
--
52 WEEK HIGH
57.50
52 WEEK LOW
13.37
MARKET CAP
2.19B
P/E (TTM)
-14.5695
1D
5D
1M
3M
1Y
5Y
1D
Dianthus Therapeutics nimmt am Guggenheim Emerging Outlook: Biotech Summit teil
Reuters · 2d ago
Dianthus Therapeutics Is Maintained at Buy by Jefferies
Dow Jones · 5d ago
Dianthus Therapeutics Price Target Raised to $81.00/Share From $66.00 by Jefferies
Dow Jones · 5d ago
Jefferies Maintains Buy on Dianthus Therapeutics, Raises Price Target to $81
Benzinga · 5d ago
Weekly Report: what happened at DNTH last week (0126-0130)?
Weekly Report · 5d ago
DIANTHUS THERAPEUTICS INC <DNTH.O>: JEFFERIES RAISES TARGET PRICE TO $81 FROM $66
Reuters · 5d ago
Pipeline-in-a-Product Momentum: De-Risked Autoimmune Neurology Catalyst Path Justifies Buy Rating on Claseprubart Franchise
TipRanks · 01/29 17:25
DIANTHUS THERAPEUTICS <DNTH.O>: OPPENHEIMER RAISES TARGET PRICE TO $125 FROM $62
Reuters · 01/29 13:19
More
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Webull offers Dianthus Therapeutics Inc stock information, including NASDAQ: DNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNTH stock methods without spending real money on the virtual paper trading platform.